Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.38 |
| ▸ | USP2 | O75604 | 7/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 6/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10168682 | 0.98 | USP2 (0.39) | CYP3A4USP2CYP2D6CYP1A2TP53 | |
| SCHEMBL12911787 | 0.95 | CYP2D6 (0.34) | CYP3A4USP2CYP2D6CYP1A2TP53 | |
| SCHEMBL19194368 | 0.93 | CYP3A4 (0.33) | CYP3A4USP2CYP2D6CYP1A2TP53 | |
| SCHEMBL9963381 | 0.93 | CYP2D6 (0.39) | CYP3A4USP2CYP2D6CYP1A2TP53 | |
| SCHEMBL12911788 | 0.93 | CYP2D6 (0.39) | CYP3A4USP2CYP2D6CYP1A2TP53 | |
| SCHEMBL24789561 | 0.91 | HRH3 (0.35) | CYP3A4USP2CYP2D6CYP1A2TP53 | |
| SCHEMBL19194218 | 0.91 | CYP2D6 (0.34) | CYP3A4USP2CYP2D6CYP1A2TP53 | |
| SCHEMBL13910198 | 0.91 | CYP2D6 (0.34) | CYP3A4USP2CYP2D6CYP1A2TP53 | |
| SCHEMBL19194369 | 0.91 | CYP2D6 (0.34) | CYP3A4USP2CYP2D6CYP1A2TP53 | |
| SCHEMBL14524120 | 0.91 | HRH3 (0.36) | CYP3A4USP2CYP2D6CYP1A2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230203039-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | BRISTOL MYERS SQUIBB CO (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-08-05 | — | — | US | disclosed |
| WO-2019043018-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) | 2019-03-07 | — | — | WO | disclosed |
| US-20190070178-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2019-03-07 | — | — | US | disclosed |
| US-9963448-B2 | Bicyclic inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9856267-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170320883-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2017-11-09 | — | — | US | disclosed |
| US-20170283425-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-10-05 | — | — | US | disclosed |
| US-20110251386-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | SHIONOGI & CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-8017638-B2 | Isoxazole derivative and isothiazole derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1 | SHIONOGI & CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-8017638-B2 | Isoxazole derivative and isothiazole derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1 | SHIONOGI & CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110015178-A1 | Amido-Thiophene Compounds and Their Use | THE UNIVERSITY OF EDINBURGH (GB) | 2011-01-20 | — | — | US | disclosed |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | THE UNIVERSITY OF EDINBURGH | 2010-10-21 | — | — | US | disclosed |
| US-20100240659-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 11SS-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| US-20100197662-A1 | HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | SHIONOGI & CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | SHIONOGI & CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240659-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 11SS-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORY ACTIVITY | HSD11B1, HSD3B1, SRD5A1 | CYP3A4 121/4885USP2 2934/4885CYP2D6 182/4885 |
| US-20110251386-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | LIPG, CEL, LIPA | CYP3A4 741/4885USP2 539/4885CYP2D6 581/4885 |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | IAPP, SLC5A2, SLC2A2 | CYP3A4 4379/4885USP2 345/4885CYP2D6 4525/4885 |
| US-20110015178-A1 | Amido-Thiophene Compounds and Their Use | HSD11B1, HSD11B2, HSD17B1 | CYP3A4 631/4885USP2 4001/4885CYP2D6 646/4885 |
| US-20100197662-A1 | HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | HSD11B1, HSD3B1, HSD11B2 | CYP3A4 208/4885USP2 2868/4885CYP2D6 199/4885 |
| US-20230203039-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | PADI4, PADI1, PADI2 | CYP3A4 85/4885USP2 986/4885CYP2D6 429/4885 |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | HSD3B1, NR5A1, HSD11B1 | CYP3A4 138/4885USP2 3636/4885CYP2D6 171/4885 |
| US-20170320883-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | CYP3A4 1387/4885USP2 2753/4885CYP2D6 1699/4885 |
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | HSD17B1, HSD11B1, HSD3B1 | CYP3A4 136/4885USP2 4142/4885CYP2D6 85/4885 |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | CYP7A1, SLC10A1, CYP11B2 | CYP3A4 35/4885USP2 4318/4885CYP2D6 9/4885 |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | HSD11B1, HSD11B2, HSD17B1 | CYP3A4 386/4885USP2 3580/4885CYP2D6 437/4885 |
| US-20170283425-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | PPIG, PPIH, FKBP2 | CYP3A4 1985/4885USP2 1179/4885CYP2D6 1688/4885 |
| US-20190070178-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | CYP3A4 1395/4885USP2 2650/4885CYP2D6 1593/4885 |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI2, PADI6 | CYP3A4 233/4885USP2 538/4885CYP2D6 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.